Supplements During Cancer: Help or Hype?
September 14, 2011 – Laura Beil
Unlocking the Mystery of Cancer Stem Cells
September 14, 2011 – Elaine Schattner, MD
Advocates Make Cancer Their Mission
September 14, 2011 – Marc Silver
Choosing an Imaging Test
September 14, 2011 – Charlotte Huff
Do You Need a Cancer Coach?
September 14, 2011 – Jennifer M. Gangloff
Coordinating Care After Cancer
September 14, 2011 – Dawn Dorsey
How to Manage Family Dynamics During Cancer
September 14, 2011 – Jane Hill
Another State Gets Chemo Parity
September 14, 2011 – Taylor Walker
Ford Led Discussion on Breast Cancer
September 14, 2011 – Lindsay Ray
Currently Viewing
Breast Cancer Drug Scores Win in Prevention
September 14, 2011 – Elizabeth Whittington
A Survivorship Resource Map
September 14, 2011 – Elizabeth Whittington
Q & A: Patients Want Coordinated Care
September 14, 2011 – Len Lichtenfeld, MD
San Antonio Breast Cancer Symposium
September 14, 2011 – Lindsay Ray
The Meaning of Stem Cells
September 14, 2011 – Debu Tripathy, MD
Comments from Readers
September 14, 2011
Managing Cancer-Related Diarrhea
September 14, 2011 – Katy Human
Supplement Research in Cancer Lacking
September 14, 2011 – Barrie Cassileth, PhD
Pipeline
September 14, 2011 – Lindsay Ray
Remaining Faithful
September 14, 2011 – Cheryl L. Rice
Açaí Berry’s Effect on Cancer in Question
September 14, 2011 – Jason Roberson
What Caused Your Cancer?
September 14, 2011 – Staff Reports
Searching for a Cancer Coach?
September 14, 2011 – Jennifer M. Gangloff
Tell What You’re Taking
September 14, 2011 – Laura Beil
Don’t Believe Everything You Read on Supplement Labels
September 14, 2011 – Laura Beil
Understanding Clinical Trials
September 14, 2011
Checking Out a Charity
September 14, 2011 – Marc Silver
Should You “Just Do It?”
September 14, 2011 – Marc Silver
Previvors Need Expert Guidance, Close Surveillance
September 14, 2011 – Dawn Dorsey
Safety in Numbers
September 14, 2011 – Jane Hill
Flaxseed Doesn't Help With Hot Flashes
September 14, 2011 – Kathy LaTour
From Our Archives: Imaging
September 16, 2011
From Our Archives: Supplements
September 14, 2011
Vitamin D and Folate May Reduce Colon Cancer Risk
September 14, 2011 – Lena Huang
Sleep Problems Impair Childhood Cancer Survivors
September 14, 2011 – Taylor Walker
Cancer Imaging Gets Sophisticated
September 14, 2011 – Susan R. Peck, PhD
From Our Archives: Advocacy
September 14, 2011

Breast Cancer Drug Scores Win in Prevention

Aromasin (exemestane) reduces the risk of post-menopausal breast cancer. 

BY Elizabeth Whittington
PUBLISHED September 14, 2011

Aromasin (exemestane) not only reduces the risk of recurrence of hormone-positive breast cancer in post-menopausal women, it also helps prevent the disease from developing.

Study results, which were released at the annual meeting of the American Society of Clinical Oncology (ASCO) in June, revealed that the aromatase inhibitor lowered the relative risk of breast cancer by about two-thirds. Results were also published in The New England Journal of Medicine.

Paul Goss, MD, PhD, lead investigator of the MAP.3 trial, said the drug, when compared with a placebo, lowered the risk of breast cancer after three years from 55 cases per 10,000 women to 19. “Exemestane offers a new option for consideration of breast cancer prevention for [post-] menopausal women,” and women and their doctors should be aware of this option for breast cancer prevention, he told ASCO attendees during the study presentation.

Two other drugs, tamoxifen and Evista (raloxifene), lower the risk of breast cancer by about 38 to 50 percent. Both drugs are approved by the Food and Drug Administration as chemoprevention, but rare, serious side effects, such as blood clots and stroke, have hindered the widespread adoption of these drugs for women who are at high risk for breast cancer. Although Evista, which is also approved for osteoporosis, has a lower risk of these side effects, it is not commonly prescribed for this indication. 

Aromasin has its own risk of side effects, although less severe, with the most common including hot flashes, fatigue, bone mineral loss and joint pain. The drug recently went off patent, and a generic version of the drug became available in May.

Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Breast Cancer CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In